Biogen to present late-breaking litifilimab Phase 2 AMETHYST data at AAD Annual Meeting
Reuters
Mar 19
Biogen to present late-breaking litifilimab Phase 2 AMETHYST data at AAD Annual Meeting
Biogen will attend the American Academy of Dermatology Annual Meeting on March 27-31, 2026.
Late-breaking Phase 2 AMETHYST Part A results on litifilimab in cutaneous lupus erythematosus are scheduled for an oral presentation on March 28, 2026 at 3:24 PM MT.
The release was posted at .
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190730PRIMZONEFULLFEED9674850) on March 19, 2026, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.